Cost Effectiveness of Latest Recommendations for Group B Streptococci Screening in the United States

Obstet Gynecol. 2020 Aug;136(2):429. doi: 10.1097/AOG.0000000000004035.

Authors

Anne Regenstein¹, Rachel Mirsky

Affiliation

¹ Department of Obstetrics and Gynecology, Kaiser Permanente, San Francisco, California.

PMID: 32732760
DOI: 10.1097/AOG.0000000000004035

No abstract available

Publication types

Comment

MeSH terms

Cost-Benefit Analysis
Humans
Mass Screening*
Streptococcus agalactiae*
United States